Achiron Asaf, Lagstein Oded, Glick Mirit, Gur Zvi, Bartov Elisha, Burgansky-Eliash Zvia
Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Ophthalmol. 2015 Dec;93(8):e649-53. doi: 10.1111/aos.12735. Epub 2015 Apr 20.
To quantify subjective visual metamorphopsia in newly diagnosed patients suffering from diabetic macular oedema (DME) and other macular abnormalities and to evaluate anti-VEGF treatment effect.
Patients with DME, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or retinal venous occlusion (RVO) were recruited. Metamorphopsia score (Mscore) was calculated using M-Charts at baseline and at the end of a series of anti-VEGF injections.
Fifteen eyes of 10 patients with DME, 14 eyes of 13 patients with AMD-CNV and five patients with RVO were included in this study. At baseline, positive Mscore was observed in 46.6% of eyes with DME, 50% of eyes with AMD-CNV and four of five eyes with RVO. Treatment led to a complete metamorphopsia reduction (Mscore = 0) in 71.4% of DME patients, 35.7% of AMD and 0% of RVO patients.
We suggest that the M-charts may serve as an additional test for diagnosis and follow-up, complementary to morphological evaluation by imaging, in diabetic patients facing their first anti-VEGF treatment.
量化新诊断的糖尿病性黄斑水肿（DME）及其他黄斑异常患者的主观视觉变形，并评估抗血管内皮生长因子（VEGF）治疗效果。
招募患有DME、年龄相关性黄斑变性（AMD）继发的黄斑下脉络膜新生血管（CNV）或视网膜静脉阻塞（RVO）的患者。在基线期以及一系列抗VEGF注射结束时，使用M图表计算变形评分（Mscore）。
本研究纳入了10例DME患者的15只眼、13例AMD-CNV患者的14只眼以及5例RVO患者。基线时，46.6%的DME患眼、50%的AMD-CNV患眼以及5例RVO患者中的4只患眼观察到正Mscore。治疗使71.4%的DME患者、35.7%的AMD患者和0%的RVO患者的变形完全减轻（Mscore = 0）。
我们建议，对于首次接受抗VEGF治疗的糖尿病患者，M图表可作为一种额外的诊断和随访检测方法，补充影像学形态学评估。
